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The LIMD1 protein bridges an association between the
prolyl hydroxylases and VHL to repress HIF-1 activity
Daniel E. Foxler1,8, Katherine S. Bridge1,8, Victoria James1,8, Thomas M. Webb2,8, Maureen Mee1,
Sybil C. K. Wong1, Yunfeng Feng3, Dumitru Constantin-Teodosiu1, Thorgunnur Eyfjord Petursdottir4,
Johannes Bjornsson4, Sigurdur Ingvarsson5, Peter J. Ratcliffe6, Gregory D. Longmore3 and Tyson V. Sharp1,7,9
There are three prolyl hydroxylases (PHD1, 2 and 3) that
regulate the hypoxia-inducible factors (HIFs), the master
transcriptional regulators that respond to changes in
intracellular O2 tension1,2. In high O2 tension (normoxia) the
PHDs hydroxylate two conserved proline residues on HIF-1α,
which leads to binding of the von Hippel–Lindau (VHL) tumour
suppressor, the recognition component of a ubiquitin–ligase
complex, initiating HIF-1α ubiquitylation and degradation3–6.
However, it is not known whether PHDs and VHL act separately
to exert their enzymatic activities on HIF-1α or as a
multiprotein complex. Here we show that the tumour
suppressor protein LIMD1 (LIM domain-containing protein)
acts as a molecular scaffold, simultaneously binding the PHDs
and VHL, thereby assembling a PHD–LIMD1–VHL protein
complex and creating an enzymatic niche that enables efficient
degradation of HIF-1α. Depletion of endogenous LIMD1
increases HIF-1α levels and transcriptional activity in both
normoxia and hypoxia. Conversely, LIMD1 expression
downregulates HIF-1 transcriptional activity in a manner
depending on PHD and 26S proteasome activities. LIMD1
family member proteins Ajuba and WTIP also bind to VHL and
PHDs 1 and 3, indicating that these LIM domain-containing
proteins represent a previously unrecognized group of
hypoxic regulators.
LIMD1 is a tumour suppressor andmember of the Ajuba family of LIM
domain-containing proteins7,8. This family of proteins is characterized
by three conserved carboxy-terminal LIM domains involved in
protein–protein interactions arrayed in tandem in addition to a less
well-characterized and divergent proline/serine-rich amino-terminal
(pre-LIM) region9,10. A yeast two-hybrid screen identified PHD1
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as a specific binding partner of LIMD1 (Supplementary Fig. S1a).
As LIMD1 shares homology with Ajuba family member proteins
Ajuba and WTIP, and within the LIM-domain region with the zyxin
LIM domain-containing family members TRIP6, LPP and zyxin, we
investigated if these also bound PHD enzymes. We carried out in vivo
co-immunoprecipitation assays with Xpress-tagged family member
proteins and PHD1, 2 and 3 and discovered differential binding of the
PHDs to the family members (Fig. 1a). LIMD1 bound all three PHDs,
whereas the closely related WTIP and Ajuba only bound PHD1 and 3.
Out of the more distantly related zyxin family members, the only inter-
action detected was between TRIP6 and a modified higher-molecular-
weight form of PHD1 of unknown function (denoted by an arrow in
Fig. 1a). Owing to the homology of the PHD family members and the
demonstration that PHD2 is the critical oxygen sensor responsible for
the regulation of HIFα (refs 11,12), we focused our attention on this
hydroxylase together with LIMD1 (which bound all three PHDs). In a
direct binding assay recombinant LIMD1 bound directly to glutathione
S-transferase (GST)–PHD2 in vitro (Supplementary Fig. S1b–d).
On the basis of these findings we asked if LIMD1’s tumour-
suppressive function could, in part, be through formation of a
PHD–LIMD1–VHL active complex regulating the HIF-1α degra-
dation pathway, and thus one or more of the many downstream
HIF-target genes that have pro-angiogenic, pro-metastatic or other
oncogenic functions13. To test this possibility, we first immuno-
precipitated endogenous PHD2 and found endogenous LIMD1 to
co-immunoprecipitate in addition to a higher-molecular-weight form
of LIMD1 of unknown modification (most probably representing
phosphorylated forms14, unpublished data; Fig. 1b). Immunopre-
cipitation of endogenous VHL from HEK293 cells resulted in the
co-precipitation of elongin B, cullin 2, LIMD1 and PHD2, further
supporting the presence of this complex in cells (Fig. 1c). Furthermore,
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sucrose-gradient analysis of HEK293 cell extracts demonstrated that
LIMD1 was present in the same fractions as PHD2, VHL, elongin B and
cullin 2 (Supplementary Fig. S1e). These biochemical data supported
the existence of a PHD2–LIMD1–VHL complex and also corroborate
an earlier in vivo study, where PHD2 purified in a complex with an
apparent relativemolecularmass aboveMr 300,000 (300K) (ref. 15).
The members of the Ajuba family function as protein adapters,
simultaneously binding multiple proteins to enable specific regulatory
processes10,16. To assess if this function was applicable to HIF-1
regulation we examined if those family members able to bind
one or more of the PHDs were also able to bind VHL. In vivo
co-immunoprecipitation revealed that both the p19 and p30 isoforms
of VHL (refs 17,18) bound specifically to LIMD1, Ajuba andWTIP but
not zyxin or LPP (Fig. 1d). To further validate the endogenous VHL
and LIMD1 interaction we also identified this association in HeLa and
U2OS cells (Supplementary Fig. S13f,g). These data therefore support
the concept that LIMD1 is part of a complex that contains the VHL E3
ligase. Of note, we repeatedly observed multiple forms of LIMD1 and
VHL in these endogenous co-immunoprecipitation studies (Fig. 1b,c
and Supplementary Fig. S1f,g). These multiple co-precipitated forms
of LIMD1 and VHL were specific, as neither control experiments that
probed the immunoprecipitating antibodies alone nor experiments
carried out in the VHL-deficient RCC4 cell line showed any non-
specific cross-reactivity (Supplementary Fig. S1i–k). The multiple
forms of VHL match those observed in the sucrose-gradient analysis
and have previously been reported19. The higher-molecular-weight
forms of LIMD1 appear only on concentration of the complex
through immunoprecipitation and thus may be specifically modified
as a result of complex formation. Such an association between
LIMD1 and VHL would predict that they form a functional E3
ligase complex. Consistent with this hypothesis, we detected increased
HIF-1α ubiquitylation following LIMD1 overexpression (Fig. 1e). A
PHD2/VHL non-binding mutant (1186–2201LIM2, see below) was
unable to induce ubiquitylation (Fig. 1e).
We next sought to determine which region of LIMD1 mediates its
association with PHD2 and VHL. In vivo co-immunoprecipitation
studies with the pre-LIM region of LIMD1 (LIMD11472–676)
and LIM-domain region (LIMD111–467; Fig. 1f) revealed PHD2
bound to the pre-LIM region (Fig. 1g) and VHL bound to the
LIM-domain region (Fig. 1h). These data together with the endogenous
co-immunoprecipitation and sucrose-gradient data suggest that
LIMD1 may be able to simultaneously bind PHD2 and VHL and
therefore may enhance the co-operative function of both proteins by
increasing their local concentration, enabling more efficient sequential
modification and degradation of HIF-1α. As VHL does not associate
directly with PHDs, this hypothesis predicts that the presence of LIMD1
would enable VHL to associate in a complex also containing PHD2
in vivo. In ectopic expression studies, immunoprecipitation of VHL in
the absence of transfected plasmids encoding LIMD1 resulted in only
very low levels of associated PHD2 (Fig. 1i); however, when plasmids
encoding LIMD1 were co-transfected this resulted in significantly
increased co-precipitation of PHD2 with VHL (Fig. 1i). Furthermore,
immunoprecipitation of transfected plasmids encoding LIMD1 in the
presence of PHD2 and VHL resulted in the association of both proteins
with LIMD1 and importantly neither impaired the other’s ability to
bind LIMD1 (Supplementary Fig. S1l,m), as would be expected if both
proteins interacted with distinct regions of LIMD1 (Fig. 1g,h) and
if LIMD1 acts as an adapter for both proteins. LIMD1 did not bind
full-lengthHIF-1α or its separate sub-domains as determined by in vivo
co-immunoprecipitation (Supplementary Fig. S2a,b).
We next tested if overexpression of LIMD1 affected HIF-1
transcriptional activity. Ectopic expression of LIMD1 with HIF-1α
resulted in significantly reduced hypoxic response element (HRE)-
driven luciferase reporter activity (Fig. 2a). This was specific for LIMD1,
as LPP (PHD/VHLnon-binder) did not cause any significant repression
(Fig. 2b). Furthermore, HRE transcription in the presence and absence
of co-expressed PHD2 indicated that the negative effect of LIMD1 on
HIF-1α transcriptional activity was additive with exogenous PHD2
(Fig. 2b). Western blot analysis of the reporter lysates revealed that
LIMD1 caused a decrease inHIF-1α levels (Supplementary Fig. S2c)
To corroborate the LIMD1 ectopic-expression studies we carried
out the converse analysis in cell lines specifically depleted for LIMD1
using lentiviral-driven short hairpin RNA (shRNA) technology and,
as a control for potential off-target effects of LIMD1 depletion,
in the absence or presence of RNA interference (RNAi)-resistant
LIMD1 (rrLIMD1) expressed from the same lentiviral vector20
(Fig. 2c). Depletion of LIMD1 either in normoxia (20% O2) or
hypoxia (1% O2) resulted in increased HIF activity, which was
restored (or in fact significantly repressed) by concurrent expression
of RNAi-resistant LIMD1 (Fig. 2c). As predicted by the action of
LIMD1 on HIF-1α degradation (Supplementary Fig. S2c), short
interfering RNA (siRNA)-targeted depletion of endogenous LIMD1
increased endogenous HIF-1α protein levels in normoxia (Fig. 2d)
and was comparable to that observed following siRNA-targeted
depletion of PHD2 (Fig. 2e).
When LIMD1-depleted cells were exposed to hypoxia we observed
a greatly exaggerated increase in HIF-1α protein levels (Fig. 2f).
This result would at first seem paradoxical owing to the inability
of VHL to recognize and ubiquitylate unmodified HIF-1α at 1%
oxygen. However, it is now clear that in both acute and chronically
hypoxic cells PHD2 activity is still present, acting to degrade HIF-1α
(refs 21–23). In addition, VHL can engage HIF-1α in hypoxia and
promote VHL-mediated HIF-1α ubiquitylation and degradation24.
We therefore reasoned that the PHD2–LIMD1–VHL complex may
also be functional in hypoxia, potentially as part of the adaptive
response to chronic hypoxia, and that depletion of LIMD1 in
these conditions would disrupt the complex, leading to further
HIF-1α stabilization. To test this possibility, we recapitulated the
experiments of ref. 22 with siRNA-targeted depletion of LIMD1
in acute and chronic hypoxia (4–72 h at 1% O2; Fig. 2g). These
experiments revealed that LIMD1 depletion, similarly to PHD2
depletion, caused a significant stabilization of HIF-1α protein in
both acute and chronic hypoxia (in addition to normoxia) and
inhibited adaptation to chronic hypoxia (Fig. 2g; compare HIF-1α
expression in control lanes with siRNA depletion of LIMD1 and
PHD2 over time in hypoxia). Furthermore, HIF-1α degradation
was inhibited following re-oxygenation of hypoxic cells depleted of
LIMD1 (Supplementary Fig. S3a). These results therefore suggest
that in hypoxia a significant proportion of cellular HIF-1α continues
to undergo LIMD1-dependent degradation; of this only a small
proportion is stabilized under hypoxic conditions. The two distinct
molecular-weight forms of HIF-1α consistently observed in the above
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Figure 1 The Ajuba/zyxin family members interact differentially with PHD1–3
and VHL. (a) Plasmids encoding Xpress-tagged Ajuba/zyxin family members
were co-transfected with untagged pcDNA3–PHD1, 2 or 3 into U2OS
cells. 1% inputs loaded indicate protein levels before addition of the
immunoprecipitating (IP) Xpress antibody. The family members interact
differentially with the PHDs, with LIMD1 being the only family member
to bind all three and the only member to bind PHD2. (b) Endogenous
PHD2 was immunoprecipitated with PHD2 antibody (5 µg) from HEK293,
HeLa or U2OS cell lysates. Endogenous LIMD1 co-immunoprecipitated
with endogenous PHD2 in all the cell lysates assayed. (c) Endogenous
VHL was immunoprecipitated from HEK293 cell lysate with VHL antibody
(5 µg). VHL co-immunoprecipitated endogenous LIMD1 and the VCB complex
proteins elongin B and cullin 2. (d) The indicated family members were
co-transfected with VHL into U2OS cells. Both the p30 and p19 VHL
isoforms were expressed. The family members were immunoprecipitated with
Xpress antibody. LIMD1, Ajuba and WTIP all bound to the p19 and p30 forms
of VHL. TRIP6 only bound the p30 form (longer-exposure panel) and zyxin
and LPP did not bind to either. (e) Ubiquitylation assay of V5–HIF-1α. Lysates
from HEK293 cells transfected with V5–HIF-1α vector were mixed with
lysates from cells co-transfected with Flag–ubiquitin vector and incubated
at 37 ◦C. Immunoprecipitation was carried out with V5 antibody and western
blot with Flag antibody. (f) Schematic representation of LIMD1 depicting
the three C-terminal LIM domains and a non-conserved pre-LIM region.
NES, nuclear export signal. The interface within LIMD1 responsible for
binding with PHD2 and VHL was examined using Xpress-tagged wild-type
LIMD1, pre-LIM (1472–676) and LIM domain-only mutants (11–467).
(g,h) The Xpress constructs were immunoprecipitated with Xpress antibody.
Arrows indicate specific bands in lane 3 (LIMD11472–676). PHD2 binds
to LIMD1 through the pre-LIM domain (g) whereas VHL interacts through
the LIM domain (h). (i) V5-tagged VHL was immunoprecipitated using a
V5 antibody, following co-transfection with plasmids encoding LIMD1 or
PHD2 individually and in combination. LIMD1 co-immunoprecipitated with
VHL regardless of ectopically expressed PHD2. Co-immunoprecipitation of
PHD2 was significantly enhanced with overexpressed LIMD1, suggesting
that LIMD1 simultaneously binds VHL and PHD2 into a protein complex.
(j) Illustration of PHD2–LIMD1–VHL complex and co-immunoprecipitation
approach used. In all panels, VO or − indicates vector only/empty vector was
added as control.
assays (arrows, Fig. 2e–g and Supplementary Fig. S3a) are due to
HIF-1α phosphorylation25–28 as determined by λ-protein phosphatase
treatment (Supplementary Fig. S3b).
In normoxia, degradation of HIF-1α is a result of hydroxylation
and ubiquitylation within the oxygen-dependent degradation domain
(ODD) of HIF-1α (refs 6,29). As expression of LIMD1 decreases
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Figure 2 LIMD1 is a negative regulator of HIF-1α levels and transcription
activity. (a) Ectopic co-expression of LIMD1 with HIF-1α represses
synthetic pGL3-HRE-luc activity in normoxia and hypoxia when compared
with expression of HIF-1α alone. HRE-luc was normalized to a thymidine
kinase (TK)-driven Renilla luciferase. Data are mean ± s.d., n = 3
independent experiments, ∗P < 0.005. (b) Plasmids encoding LIMD1
or LPP were co-transfected plus or minus 1 ng of PHD2. LIMD1 and
PHD2 caused HRE repression in an additive manner. LPP did not cause
HRE repression and when co-transfected with plasmids encoding PHD2
the level of repression was similar to that for PHD2 expression alone.
Data are mean ± s.d., n = 3 independent experiments, ∗P < 0.005,
∗∗P <0.05. (c) Lentiviral-driven shRNAs (A and B) were used to deplete
endogenous LIMD1 and rescue with an RNAi-resistant LIMD1 in U2OS
cells as confirmed by western blot. LIMD1 shRNA A and B represent
shRNAs that target different sites within the LIMD1mRNA 3′ untranslated
region (3′UTR) and 5′UTR respectively. Rescue experiments were carried
out on the shRNA B-depleted background. shRNA-mediated LIMD1
depletion results in enhancement of synthetic pGL3-HRE-luc activity
in both normoxia and hypoxia. This is reversed by re-expression of
an RNAi-resistant LIMD1. Data are mean ± s.d., n = 3 independent
experiments, ∗P < 0.005,∗∗P < 0.05. (d,e) siRNA (80nM)-mediated
depletion of LIMD1 in U2OS (d) and HEK293 (e) cells causes an increase
in HIF-1α protein levels in normoxia comparable to that caused by
siRNA depletion of PHD2. SCR, scrambled. (f) siRNA-mediated depletion
of LIMD1 (80nM) in U2OS cells also caused an increase in HIF-1α
protein levels in hypoxia and had no effect on HIF-1β protein levels.
(g) siRNA-mediated depletion of LIMD1, PHD2 or both caused an increase
in HIF-1α protein levels in normoxia and up to 72h hypoxia.
HIF-1α levels (Supplementary Fig. S2c), we asked if increased LIMD1
expression would have a specific negative effect on stability of the
ODD domain of HIF-1α alone. Expression of LIMD1 resulted in
reduced levels of ODD, but not of the amino (amino acids 30–389)- or
carboxy (amino acids 630–826)-terminal domains (Fig. 3a). In contrast,
TRIP6, which does not bind PHD2 (Fig. 1a), did not induce ODD
degradation (Fig. 3a,c).
We next used the shRNA lentiviral-infected cell lines to test the
converse prediction with respect to ODD protein levels and LIMD1
expression. Depletion of LIMD1 resulted in an increase in ODD
expression (arrowhead) that is reduced with re-expression of rrLIMD1
(Fig. 3b). Family members Ajuba and WTIP, which bind both PHD
andVHL, were also able to induceODDdegradation (Fig. 3c).
The dependence on hydroxylase and proteasomal activities for
LIMD1-mediated regulation of ODD levels was examined next. In
the presence of DMOG (a competitive inhibitor of 2-oxoglutarate
(2-OG)-dependent oxygenases) or MG132 (a 26S proteasome
inhibitor), LIMD1, Ajuba, WTIP and PHD2 were unable to induce
a reduction in ODD levels, confirming a requirement for both
enzymatic activities (Fig. 3d,e).
A further prediction of our proposed PHD2–LIMD1–VHL complex
would be that PHD2/VHL-non-binding LIMD1 mutants would be
unable to induce degradation of ODD or HIF, deregulate HIF activity
in reporter assays or may even act in a dominant inhibitory manner. To
create non-binding mutants in the context of full-length LIMD1 the in-
ternal binding sites within LIMD1 were mapped for PHD2 (1186–260)
and VHL (1LIM2; Supplementary Fig. S4a,b, respectively).
As predicted, the double PHD2/VHL non-binding mutant
(1186–260–1LIM2) did not induce ODD degradation when
overexpressed in the presence of endogenous LIMD1 (Fig. 3f),
indicating the requirement of associated PHD hydroxylase and/or
VHL ubiquitin-ligase activities for LIMD1 to regulate this pathway.
In an endogenous LIMD1-depleted background the capability of
rrLIMD1 (expressed at levels comparable to endogenous LIMD1)
to degrade ODD was lost on rescue with rr1186–260–1LIM2 or
rr1LIM2 mutants (Fig. 3g). In contrast, rescue with rr1186–260
alone was able to influence ODD degradation. These results suggest
that the VHL association with LIMD1 is pivotal for LIMD1-induced
HIF degradation, and could also suggest a LIMD1-independent PHD
modification of HIF-1α. These ODD results were mirrored when the
same cell lines were analysed for HRE activity in normoxia (Fig. 3h).
Interestingly, when the same assay was carried out under hypoxia
the rr1LIM2 mutants resulted in a dominant negative effect on
HRE-luc transcription (Fig. 3 compare h and i). This indicated (1)
that in hypoxia engaging VHL is critical or (2) that the ability to
bind and sequester PHD2 away from VHL may further stabilize
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Figure 3 LIMD1-induced ODD degradation is dependent on PHD,
proteasomal activities and PHD2/VHL binding. (a) Plasmids encoding
Xpress-tagged LIMD1 or TRIP6 and haemagglutinin (HA)–HIF-1α N-
(amino acids 30–389), ODD (amino acids 390–652) or C-terminal (amino
acids 630–826) domains were co-transfected into U2OS cells. Ectopic
expression of LIMD1 (but not TRIP6) induces a specific reduction in
ODD, but not in N- or C-terminal domains. (b) Plasmids encoding
HIF-1α N-, ODD or C-terminal domains were transfected into lentiviral
shRNA B-mediated LIMD1-depleted and rescued U2OS cell lines. LIMD1
depletion resulted in stabilization of the ODD domain, denoted by the
arrow. LIMD1 protein depletion had no effect on the N- or C-terminal
HIF-1α domains. SCR, scrambled. (c) Plasmids encoding the indicated
family members and PHD2 as a positive control were co-transfected into
U2OS cells with HA–ODD. PHD2 expression resulted in degradation of
the ODD, whereas TRIP6 expression (negative control) did not. (d,e) The
ability to induce ODD degradation is dependent on hydroxylase and 26S
proteasome activity, as ODD degradation was not observed when cells were
treated with the PHD2 inhibitor DMOG (d) or the 26S proteasome inhibitor
MG132 (e). (f) Plasmids encoding Xpress-tagged wild-type LIMD1 or LIMD1
unable to bind PHD2 and VHL (1186–2601LIM2) were co-transfected
with HA–ODD into U2OS cells. (g) U2OS cell lines stably expressing
RNAi-resistant LIMD1 or LIMD1 internal mutants that are unable to
bind PHD2 (1186–260), VHL (1LIM2) or both (1186–2601LIM2) in
a lentiviral-driven LIMD1 shRNA B-depleted background were transfected
with plasmids encoding HA–ODD. (h) The same stably expressing lentiviral
shRNA B cell lines were transfected with synthetic pGL3-HRE-luc and
TK-Renilla (for normalization). LIMD1 depletion caused an increase in
HRE transcriptional activation, which was repressed with re-expression
of an rrLIMD1. Rescue with rrLIMD1 unable to bind PHD2 and VHL
(1186–2601LIM2) increased in HRE transcriptional activation to the same
extent as LIMD1 depletion. Data are mean ± s.e.m., n = 3 independent
experiments, ∗P <0.005,∗∗P <0.05. (i) Reporter analysis as in h was also
carried out in hypoxia. (j) U2OS cells were transiently transfected with GFP
vector only, GFP–PHD2, GFP–FIH, GFP–LIMD1 and GFP–zyxin. At 44h
following transfection, cells were exposed to 1% O2 for 4 h. Cells were
then fixed and immunostained for endogenous HIF-1α and nuclear stained
using 4,6-diamidino-2-phenylindole (DAPI). Expression of LIMD1 reduced
HIF-1α expression levels and inhibited its nuclear accumulation; this was
comparable in effect to GFP–PHD2. GFP–VO and GFP–FIH do not affect
HIF-1α stability or localization. Scale bars, 20 µm.
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Figure 4 Depletion of endogenous LIMD1 induces expression of
endogenous HIF-1-targeted genes. (a) LIMD1 mRNA levels were
quantified to confirm RNAi-mediated depletion. LIMD1mRNA levels were
significantly reduced (in both normoxia and hypoxia) following LIMD1
siRNA transfection relative to cells transfected with the scrambled siRNA
control. (b) LIMD1 depletion caused a significant elevation in hypoxic
BNIP3 mRNA levels in comparison with the scrambled control; however,
no change in BNIP3 mRNA levels was observed in normoxia. (c) LIMD1
depletion induced an increase in hypoxic VEGF mRNA levels. (d) HIF-1
α mRNA levels were unaffected by LIMD1 depletion, in normoxia and
hypoxia. (e) qRT–PCR analysis of endogenous HIF-1α target genes in
HEK293 cells depleted of LIMD1 and PHD1 by RNAi and subjected to
24h at 20% or 1% O2. Data shown as fold increase when compared
with scrambled control normalized to unity. Data are mean ± s.d.,
n =3 replicates, ∗P <0.005,∗∗P <0.05. BNIP3, BCL2/adenovirus E1B
Mr19K interacting protein 3; VEGF, vascular endothelial growth factor A;
JMJD1A, jumonji domain containing 1A; WSB1, WD repeat and SOCS
box containing 1; ALDOC, aldolase C, fructose-bisphosphate; ERO1L,
endoplasmic reticulum oxidoreductin-1-like; HK1, hexokinase 1; MXI1,
MAX-interacting protein 1.
extra HIF-1α that is being hydroxylated and degraded through
LIMD1-uncomplexed PHD2/VHL.
Using a previously described immunofluorescence assay to detect
HIF-1α (ref. 30), we examined the effect of ectopic LIMD1 on
endogenous HIF-1α protein levels in vivo. Expression of green
fluorescent protein (GFP)–LIMD1 induced a reduction in HIF-1α
expression and inhibited nuclear accumulation (Fig. 3j), similar to
expression of GFP–PHD2 (Fig. 3j). As further controls, expression
of GFP only and factor inhibiting HIF (FIH) (ref. 31) had no effect
on HIF-1α expression level or localization (Fig. 3j). We believe that
the overexpression of LIMD1 enhances formation of the complex,
concentrating and recruiting any residually active PHD2 and VHL to
HIF, thus facilitating its degradation. Family member zyxin, which
does not bind VHL or PHD2, was used as a negative control (Fig. 3j,
bottom panel), showing that the ability of a protein to engage PHD2
and VHL is critical for HIF-1α degradation.
To further explore the physiological consequences of LIMD1 loss we
examined the effect of depletion of endogenous LIMD1 on endogenous
HIF-target genes (Fig. 4). siRNA-mediated LIMD1 depletion in U2OS
cells resulted in a significant increase in both BNIP3 and VEGF
messenger RNA levels in hypoxia (Fig. 4a–d). These responses were
further validated in HEK293 cells for an extra set of HIF-responsive
genes and with the inclusion of siRNA-targeted PHD2 depletion as
a further control (Fig. 4e). Of note, there were clear gene-specific
responses to LIMD1 and PHD2 depletion in both normoxia and
hypoxia (Fig. 4e), and also differences in responses of genes between
U2OS and HEK293 cell lines (Fig. 4a,b, compare BNIP3 in normoxia
on LIMD1 depletion). One possible explanation for this could be the
phosphorylation status (Supplementary Fig. S3b) and thus possible
transcriptional activity ofHIF-1 between these cell lines and also activity
towards specific responsive genes discussed above. Furthermore, a
similar observation was recently shown in ref. 32, with the same
unresponsiveness of endogenousHIF-1-responsive genes on increase in
HIF-1α level through depletion of MCM3 in normoxia, but increased
responsiveness in hypoxia (see Fig. 2k in ref. 32). Taken together, these
results indicate that reduction of endogenous LIMD1 is sufficient to
increase HIF-1α levels, HIF transcriptional activity and expression of
endogenous HIF target genes.
In summary, we have shown that theAjuba LIMproteins, particularly
LIMD1, act to facilitate assembly of a PHD2–LIMD1–VHL protein
complex that bridges the activities of PHD2 and VHL to enable
efficient modification and degradation of HIF-1α. These findings
suggest a new level in the regulation of HIF-1α whereby hydroxylation
and ubiquitylation are intimately associated enzymatic activities
in a complex, allowing for efficient and rapid post-translational
modification of HIF and its subsequent rapid degradation. Such a
model allows for further regulation of HIF-1α through regulation of
complex association/formation (Fig. 5).
HIF modification is a critical regulatory step in the cellular
response to low O2. Such a step requires tight, adaptive and diverse
regulation to enable multiple signalling pathways to impinge on the
hypoxic response with further levels of regulation. LIMD1, Ajuba and
WTIP are unique among a growing group of PHD/HIF-1α binding
proteins (Siah1/2, FKBP38 and MCM family32–35) as they are the
only regulators to simultaneously bind PHDs and VHL. Furthermore,
given differential binding to the three PHDs, the operation of such
complexes could potentially explain the fundamental paradox of how
the simple biochemical/kinetic properties of the hydroxylase–ubiquitin
ligase couple may be adapted to provide the flexibility necessary for
physiological oxygen homeostasis. 
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Figure 5 Proposed model of LIMD1-mediated/dependent degradation
of HIF-1α. (a,b) The current model depicts the prolyl hydroxylation
and subsequent VHL-mediated polyubiquitylation (Ub) as distinct and
separate processes. Under hypoxic (1%O2) conditions the activity of
PHD and thus subsequent hydroxylation/VHL-mediated ubiqutylation
is significantly reduced, resulting in stabilization of HIF-1α, which
then, dependent on cell type and conditions, becomes phosphorylated
and transcriptionally active. (c) Our proposed new model suggests that
LIMD1 interacts with PHD2 through its pre-LIM region and VHL through
the LIM domains to link the proteins into one complex. Thus, LIMD1,
Ajuba and WTIP may promote HIF-1α degradation by the proteasome,
by increasing the physical proximity of the enzymatic components
responsible for hydroxylation and ubiquitylation. For simplicity, other
proteins involved in regulating HIFα stability have not been depicted in
this model, including elongin B, C and cullin 2 within the VHL–elongin
B–elongin C complex and other Ajuba/zyxin family members. (d) Under
hypoxia we propose that LIMD1 still engages an active pool of PHD2
together with VHL to enable a degree of HIF-1α degradation in hypoxia.
However, this is not sufficient to prevent build-up and the classic
HIF-driven transcriptional response. Furthermore, this complex may
be critical for adaptation to hypoxia. (e) In normoxia with LIMD1
depletion we propose that this results in a disengagement of PHD2
from VHL, resulting in reduced efficiency of HIF-1α modification and
degradation. Under such conditions there is a significant increase of
HIF-1α levels, of which a small proportion may become phosporylated
and thus transcriptionally active. (f) In hypoxic conditions with LIMD1
depletion (compare d and f) we see a greatly exaggerated increase in
HIF-1α, which we believe indicates a loss of the LIMD1-dependent
HIF-1α degradation that occurs under hypoxic conditions. Our model
does not rule out the existence of LIMD1-independent PHD/VHL-driven
HIF-1α degradation pathways, but proposes that these are significantly
less efficient than the LIMD1-dependent one.
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METHODS
Cell culture and transfections. Human cell lines (U2OS, HeLa, HEK293,
HEK293T) were cultured in DMEM (PAA Laboratories), supplemented with
10% (v/v) fetal calf serum (Sigma), 50Uml−1 penicillin and 50 gml−1 streptomycin
(Sigma). Hypoxic treatment at 1% O2 was achieved using a ProOx 110 (BioSpherix)
controller and chamber. Proteasomal inhibition was with 10 µM MG-132 (Enzo)
for 4 h. 2-OG dioxygenase inhibition was achieved using 1mM DMOG for 4 h. For
transfected co-immunoprecipitation assays, siRNA and qRT–PCR, 2×105 U2OS or
4×105 HEK293T cells were plated into six-well plates. For transient transfection and
reporter assays, 5×104 U2OS or 8×104 U2OS shRNA lines were plated into 12-well
plates. U2OS cells were transfected using Genejuice (Merck Biosciences) or TransIT
LT1 (Mirus Bio) and HEK293T cells were transfected using TransIT 293. siRNAwas
transfected using DharmaFECT Duo or Dharma FECT 1 (Dharmacon) transfection
reagents. Transfections were as per manufacturer’s instructions.
siRNA and shRNA stable line production. The siRNA sequence (SigmaMission
siRNA) against LIMD1 was as follows: 5′-GCAAGGAGGUCUUCCAAGA-3′ (assay
code SASI_Hs01_00095038).
The shRNA sequences against LIMD1were as follows. shRNAA: hLIMD1 shRNA
3′ UTR, 5′-GCAGAATGGCTGCAAATTTAA-3′. shRNAB: hLIMD1 shRNA5′ UTR,
5′-GTCTGCAGCATGGATAAGTA-3′.
U2OS stable cell lines were generated using the lentiviral shRNA-driven LIMD1
knockdown and rescue system, as previously described36. The gene delivery and
production system was as previously described37.
Plasmids. Generation of pcDNA4/HisMax (Invitrogen) Xpress–LIMD1 and
LIMD1 deletion mutants and pcDNA3.1 PHD1, 2, 3 have previously been
described38,39. pcDNA3.1 (Invitrogen) HIF-1α, FIH, VHL, HA–enhanced GFP
(eGFP)–ODD, N-terminal HIF-1α, C-terminal HIF-1α and pGL3–HRE plas-
mids were kindly donated by Thilo Hagen, National University of Singapore.
pcDNA3.1 mLIMD1 and mLIMD1 deletion mutants, and pFLRu Scr–GFP,
hLIMD1 shRNA–GFP, hLIMD1 shRNA rrhLIMD1–FH and hLIMD1 shRNA
rrhLIMD11LIM2–FH were donated by Y. Feng and G. Longmore, Washington
University20,36. pGEX4T-1–LIMD1 and pEGFP–LIMD1 were generated as follows.
LIMD1 complementary DNA was excised from pcDNA4/HisMax–LIMD1 using
EcoRI and SalI restriction endonucleases and ligated into similarly cut pGEX4T-1
(Amersham) and pEGFP C1+ 1 vector (donated by S. Dawson, University of
Nottingham) respectively. Xpress-tagged PHD1, 2 and 3 were generated by PCR
amplification of cDNA from pcDNA3.1-PHD1,2 and 3, incorporating flanking
BamHI and EcoRI sites (for PHD3 BglII and EcoRI ) and cloned into the
pcDNA4/HisMax vector (Invitrogen). pEGFP-PHD1, 2 and 3 were generated by
restriction digest from pcDNA4/HisMax into the pEGFP vector. Xpress-tagged
LIMD1 conserved-region deletion mutants 1112–123, 1140–166, 1186–260,
1239–260, 1298–315, 1342–369, 1429–464, 1LIM2 (residues 537–591) and
double mutant 1186–260–1LIM2 were generated from pcDNA4/HisMax LIMD1
through the QuikChange site-directed mutagenesis method (Stratagene). Us-
ing the same method, pFLRu-hLIMD1 shRNA+ rrhLIMD11186–260–FH and
1LIM2–FHwere generated from template pFLRu-hLIMD1 shRNA + rrLIMD1
and subsequently pFLRu-hLIMD1 shRNA+ rrhLIMD11186–2601LIM2–FH was
generated from pFLRu-hLIMD1 shRNA+ rrhLIMD11186–260–FH.
Forward primer sequences for the mutagenesis of Xpress-tagged LIMD1
conserved-region deletion mutants were as follows:1112–123, 5′-CTTGCTGCCT-
CGACACAGCCCCCGTAC-3′; 1140–166, 5′-CCATACCTGCATCCCTGTGAGG-
ATC-3′; 1186–260, 5′-GGAGACTATTATGACAACCTCTCCTTGGGCCTTTG-
GTCCACTGCCTCCTC-3′; 1239–260, 5′-CTGAGCTCCAGCAGGGGCCTTTG-
GTCC-3′; 1298–315, 5′-AGGACCCCTTCTGTGTCGGGGCTGGGGGGTG-3′;
1342–369, 5′-CAGGATGGGCCCCCGAAGCCTGGCTGC-3′;1429–464, 5′-TCC-
CCTAGGGTAAGGAAGGCTGATTAC-3′;1 LIM2 (residues 537–591), 5′-CTGGT-
TTCCAGCAGTCGGCTGACAGGGTGCTGGCCCCCAAGTGTGCAGCC-3′. Re-
verse primers were exact reverse complements of the forward primers.
Yeast two-hybrid screen. LIMD11364–676cDNA was released from pcDNA4
/HisMax LIMD11364–676 vector and ligated into the similarly cut pAS2.1 bait
vector. The resulting plasmid (pAS2.1-LIMD1-1364–676) was pretransformed into
the Saccharomyces cerevisiae PJ69-4a (MATa trp1-90 leu2-3,112 ura3-52 his3-
200 gal4 1gal80 1LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ ) (14) reporter
strain by using a modified lithium acetate protocol (see Yeast Protocols Handbook,
BDBiosciences Clontech). Subsequently, this strainwas cotransformedwith the BC3
cDNA library (produced by using the Stratagene HybriZAP cDNA library kit) in the
GAL4DNA activation domain (GAL4AD) fusion ‘prey’ vector. Selection for positive
colonies and cDNA clone isolation were as previously described40.
Sucrose-gradient fractionation. HEK293 were lysed in 25mM Tris-HCl at pH
7.4, 150mM KCl, 0.5% NP-40, 2mM EDTA, 1mM NaF, 0.5mM dithiothreitol
supplemented with ‘Complete’ protease inhibitors (Roche) and PhosSTOP
phosphatase inhibitors (Roche)41. The cell lysate was rotated at 4 ◦C for 30min,
centrifuged at 13,000 r.p.m. for 10min, and the cleared lysate applied to a 10–35%
discontinuous sucrose gradient in polyallomer tubes. The gradient was centrifuged
at 30,000 r.p.m. for 16.5 h (SW41Ti rotor, Optima LE- 80K ultracentrifuge), and
500 µl fractions were collected from the top of the gradient (fraction number 1)
downwards to the bottom of the gradient (fraction number 17).
In vitro binding assays. pGEX4T–PHD2 and pGEX6P–LIMD1 were transformed
into BL21 (DE3)-pLysS chemically competent bacteria. Cultures were grown for
3 h before induction with IPTG followed by a further 4 h growth at 37 ◦C. Bacteria
were pelleted, freeze–thawed and lysed by sonication. Recombinant proteins were
purified onto glutathione Sepharose 4B (GE Healthcare 17-0756-01). Recombinant
LIMD1 was cleaved from the Sepharose using PreScission protease (GE Healthcare
270843) in binding buffer (50mM Tris-HCl at pH 7.0, 150mMNaCl, 1mM EDTA,
1mM dithiothreitol). Equal amounts of the cleaved recombinant LIMD1 were
incubated with either purified GST vector only or GST-PHD2 for 6 h at 4 ◦C and
washed three times with binding buffer.
Immunoprecipitations, immunoblots and immunofluorescence. For co-
immunoprecipitation of ectopically expressed proteins, cells were lysed by the
addition of ice-cold RIPA buffer (150mMNaCl, 1% (v/v) IGEPAL-630, 0.5% (w/v)
sodium deoxycholate, 0.1% (w/v) SDS, 50mM Tris, pH 8) supplemented with
‘Complete’ protease inhibitors (Roche) and PhosSTOP phosphatase inhibitors
(Roche) and scraped using a cell scraper. Lysates were rotated at 4 ◦C for 20min
and centrifuged at 13,000 r.p.m. for 10min. The cleared lysate was rotated at
4 ◦C for 4 h with immunoprecipitation matrix (Santa Cruz sc-45042) previously
conjugated to 2 µg of immunoprecipitating antibody (anti-Xpress (Invitrogen),
anti-V5 (AbD-Serotec), LIMD1 antibody (3F2/C6; ref. 39), anti-GFP (Roche)). The
immunoprecipitation matrix–antibody complex was then washed three times with
ice-cold RIPA, and protein complexes were eluted in 5×SDS–PAGE sample buffer.
For endogenous co-immunoprecipitations, cells were lysed in 1ml of RIPA buffer
supplemented with ‘Complete’ protease and phosphatase inhibitors, rotated at
4 ◦C for 30min and centrifuged at 13,000 r.p.m. for 10min. Cleared lysates were
incubated for 5 h at 4◦c with 5 µg of mouse monoclonal VHL (BD Transduction
Laboratories), PHD2 (Millipore) or matching IgG1K isotype control GFP (Roche)
antibody that had been previously conjugated to immunoprecipitation matrix
(Santa Cruz) overnight. The immunoprecipitation matrix–antibody complex was
then washed three times with ice-cold RIPA/PBS (50%v/v) and protein complexes
eluted in 5×SDS–PAGE sample buffer. SDS–PAGE and immunoblots were carried
out using standard protocols.
For immunofluorescence, cells were fixed with 4% (v/v) paraformaldehyde in
PBS at room temperature for 5min and permeabilized with 0.05% (v/v) Triton
X-100 in PBS at room temperature with gentle agitation. Cells were washed with
PBS, incubated in blocking buffer (3% (w/v) BSA, 1mM MgCl2, 1mM CaCl2 in
1× PBS) for 1 h at room temperature with gentle shaking and then washed in
washing solution (0.3% (w/v) BSA, 1mM MgCl2, 1mM CaCl2 in 1×PBS). Cells
were incubated with anti−HIF-1α (BD Transduction Laboratories, 1:500 dilution)
primary antibody and an Alexafluor (Invitrogen, 1:1,000 dilution) secondary
antibody.
Ubiquitylation assay. This assay was essentially carried out as described in
ref. 32. Briefly: cells were transfected with expression vectors encoding V5–HIF-1α,
Flag–ubiquitin, EV or Xpress–LIMD1. Cells were lysed, mixed and incubated for
1 h at 37 ◦C. Lysates were then immunoprecipitated with V5 antibody (AbD Serotec)
followed by immunoblot with antibodies toHIF-1α (BDTransduction Laboratories,
1:500 dilution) or Flag (Sigma Aldrich, 1:1,000).
Antibodies. A list of all primary and secondary antibodies and dilutions used can
be found in Supplementary Tables S1 and S2 respectively.
Reporter assays. Cells were co-transfected in triplicate with pGL3-(6x)HRE–firefly
luciferase and TK–Renilla luciferase reporters. 24 h post-transfection cells were lysed
in 1× passive lysis buffer (Promega) and freeze–thawed. Luciferase activity was
assayed using the dual luciferase reporter assay system (Promega) and TopCount
scintillation and luminescence counter (Perkin Elmer).
Phosphatase assay. Cells were exposed to 1% O2 for 16 h before lysis by scraping
in RIPA buffer supplemented with ‘Complete’ protease and phosphatase inhibitors
and 10 µMMG-132. Cleared lysates were added to 2.5 µgHIF-1α or control antibody
conjugated to immunoprecipitation matrix. Immunoprecipitation of HIF-1α was
carried out for 4 h at 4 ◦C with rotation, followed by extensive washing with
unsupplemented RIPA buffer. Dephosphorylation was carried out in 50 µlreaction
volumes using 400 units of λ protein phosphatase (NEB no P0753S) at 30 ◦C for
60min along with a control reaction that omitted the enzyme. The reaction was
stopped by addition of 5×SDS–PAGE sample buffer.
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Quantitative RT–PCR. Transfected cells were incubated for 24 h at 1% O2 or
maintained at standard incubation conditions for normoxic controls. Duplicate
wells were lysed for protein using 100 µl passive lysis buffer (Promega) and RNA
extracted using the RNAqueous micro kit (Ambion) for U2OS cells or High Pure
RNA Isolation Kit (Roche) for HEK293T cells as per manufacturer’s instructions.
RNA (1 µg) pre-treatedwithDNase I (Invitrogen)was then reverse transcribed using
oligo-dT primers and High Fidelity Reverse Transcriptase (Roche). To quantify the
mRNA levels of target genes quantitative real-time PCR was conducted using 1×
Power SYBR Green Mastermix (Applied Biosystems), 0.4mM forward and reverse
primers, 2.5 µl cDNA and dH2O to a final volume of 25 µl; reactions were run on an
ABI7000 instrument (Applied Biosystems). U2OS cells were transfected with 80 nM
of scrambled control and LIMD1 siRNA. 40 h post-transfection, cells were incubated
in normoxia (20% O2) or hypoxia (1% O2) for 8 h. Cells were lysed and RNA
extracted using the RNAqueous microRNA extraction kit (Ambion). Quantitative
RT–PCR (qRT–PCR) was carried out using gene-specific primers spanning an exon
boundary and SYBR Green I. Data were normalized to the housekeeping genes
RNA polymerase II and β-tubulin and analysed using the relative quantification
method 2-[delta][delta]Ct. The list of qRT–PCR primer sequences used can be found as
Supplementary Table S3.
Statistical analysis. For reporter assays, firefly luciferase values were normalized
against Renilla luciferase values. Error bars are the s.e.m. of the normalized values.
Data shown are the mean± s.e.m. of three independent determinations. Significant
difference was determined using the Student’s t -test.
For qRT–PCR, data were normalized to the housekeeping genes β-tubulin and
RNA polymerase II and relative quantification was determined by the comparative
cross-over threshold method (2-[delta][delta]Ct).
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Figure S1 Identification of PHD binding to LIMD1 (a) A yeast 2 hybrid 
screen of a HeLa cDNA library with a LIMD1 ∆364-676 GAL4 DNA-
binding domain identified a  cDNA encoding full length PHD1 as binding 
protein. . AD, the indicated Gal4 activation domain fusion protein. BD, 
the indicated Gal4 DNA-binding domain fusion protein. BD-LaminC fusion 
used as negative control. Interation between the indicated fusion proteins 
was assayed via auxotrphy for amino acids His and Ade with growth on 
media lacking these two (-His, -Ade) indicative of specific interaction. (b) 
recombinant GST vector only or GST-PHD2 immobilised on glutathione 
beads were incubated with (c) PreScission Protease cleaved and purified 
recombinant LIMD1(~73kDa) in an in vitro direct binding assay (d), which 
demonstrated that LIMD1 and PHD2 directly interact. (e) Sucrose gradient 
analysis of LIMD1, PHD2, VHL, elonginB and Cullin 2. HEK 293 cell lysates 
were passed through a sucrose gradient and multiple fractions recovered. 
Fractions were taken from the top (#1) to the bottom of the gradient (#17). 
Protein content of each fraction was assayed by immunoblotting with the 
indicated antibodies. LIMD1 fractionated in the same common fraction(s) 
as PHD2, VHL (both p19 and p30 isoforms), elongin B and cullin 2 (black 
boxed area).  Endogenous VHL and LIMD1 co-immunoprecipitate. VHL was 
endogenously immunoprecipitated from (f) HeLa and (g) U2OS cell lysates 
and endogenous LIMD1 co-immunoprecipitated from both lysates. In the 
HeLa lysates endogenous elonginB and cullin2 also co-immunoprecipitated. 
(h) Low level expression of VHL in U2OS resulted in no detected with 
1% input loaded. However, with 2.5% input or greater detection was 
achieved. (i) As controls for the possibility of non-specific cross reactivity 
of antibodies the antibody conjugated matrices alone were probed with 
anti-LIMD1 and (j) anti-VHL antibodies. Only the heavy and light chains 
were detected with the secondary antibody, demonstrating the interactions 
observed in the immunoprecipitations (Fig. 1b, c) were specific. (k) Similar 
immunopreciptations (as in Fig. 1c) were repeated in the VHL negative RCC4 
cell lines as a negative control. No cross reactive/co-precipitated bands could 
be detected therefore further demonstrating the specificity of VHL associated 
LIMD1 and PHD2 in HEK 293 cells.  LIMD1 non-competitively interacts 
with PHD2 and VHL and enhances their association. (l) LIMD1 expression 
plasmid was co-transfected into U2OS cells with V5-VHL and pcDNA3 PHD2 
individually and in combination. LIMD1 was immunoprecipitated using an 
Xpress mAb. PHD2 and VHL co-immunprecipitated with LIMD1 individually 
and when co-expressed, with neither impairing the ability of LIMD1 to interact 
with the other. (m) Schematic representation illustrating the ability of LIMD1 
to simultaneously interact with PHD2 and VHL within a protein complex.
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Figure S2 HIF1α does not co-IP with LIMD1 in vivo. (a) Xpress-LIMD1 
was co-transfected into U2OS cells with EGFP-HIF1α. LIMD1 was 
immunoprecipitated using an Xpress mAb, following hypoxic (1% O2) or 
normoxic (20% O2) incubation for 16 hours.  HIF1α does not interact 
with LIMD1. (b) Xpress-LIMD1 was further co-transfected with the 
N- (aa30-389), ODD (390-652), or C- terminal (630-826) domains of 
HIF1α all tagged with EGFP.  Cells were incubated in hypoxia for 16 
hours to induce ODD stability and LIMD1 was immunoprecipitated with 
an Xpress mAb. None of the transfected EGFP-HIF1α domains were 
found to interact with LIMD1. (c) LIMD1 expression decreases HIF1α 
protein levels.  Reporter cell extracts expressing Xpress tagged vector 
only and LIMD1 were co-transfected with HIF1α into U2OS cells. The 
indicted reporter cell lysates from Fig. 2b western blotted with the 
indicated antibodies. 
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Figure S3 LIMD1 loss retards HIF1α degradation following reoxygenation.  
(a) Depletion of LIMD1 in U2OS cells with 80nM siRNA caused a 
stabalisation of HIF1α protein levels following 32 hours post transfection, 
cells were incubated in normoxia or hypoxia for 16 hours. Cells were taken 
out of hypoxia and into 20% O2 for the indicated times prior to lysis. LIMD1 
loss retards reoxygenation mediated degradation of HIF1α. Furthermore, 
in normoxia, HIF1α appears as a lower molecular weight than under 
hypoxic conditions. (b) Immunoprecipitation of HIF1α from hypoxic U2OS, 
HEK293 or HeLa lysates followed by phosphatase treatment resulted in a 
decrease in molecular weight as observed in (a), demonstrating the different 
molecular weights of HIF1α under different oxygen tensions are due to 
phosphorylation.
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Figure S4 Mapping of the PHD2 and VHL binding domains within 
LIMD1. Xpress vector only, wild type LIMD1 or indicated LIMD1 
deletion mutants were co-transfected with (a) GFP-PHD2 or (b) V5-VHL 
into U2OS cells. PHD2 or VHL were immunoprecipitated with GFP or 
V5 antibodies and binding of LIMD1 and mutants to PHD2/VHL was 
assayed by Western blot. PHD2 binds to within amino acids 186-260 of 
LIMD1 (∆186-260), whereas VHL binds to the second LIM domain (∆ 
LIM2).
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Figure S5 Full scans
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Supplementary Tables
Table S1 List of all Primary antibodies use in this study together with the indicated product information.
Table S2 List of all Secondary antibodies use in this study together with the indicated product information.
Table S3 qRT-PCR Primer List for indicated human genes
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